Akebia Therapeutics Q3 revenue rises

Akebia Therapeutics

10/11/2025 12:22

Overview

Akebia Q3 2025 total revenue grows to $58.8 mln, driven by Vafseo and Auryxia sales

Net income for Q3 2025 beats analyst expectations, marking a turnaround from last year

Company expects Vafseo patient access to grow to 275,000 by year-end

Outlook

Akebia expects Vafseo prescribing access to reach 275,000 patients by year-end

Company anticipates DaVita pilot completion in Q4, expanding Vafseo availability

Akebia will not pursue broad label for Vafseo in non-dialysis CKD patients

Result Drivers

VAFSEO SALES - Q3 2025 net product revenue for Vafseo reached $14.3 mln, primarily from US Renal Care

FAVORABLE OUTCOMES - Post-hoc data analysis shows Vafseo has more favorable outcomes in mortality and hospitalization compared to ESAs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.03 (5 Analysts)
Q3 Net Income
Beat
$540,000
-$8.43 mln (5 Analysts)
Q3 Operating Income
Beat
$4.45 mln
$3.08 mln (5 Analysts)
Q3 Basic EPS
Q3 Operating Expenses
$44.93 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Akebia Therapeutics Inc is $6.00, about 66% above its November 7 closing price of $2.04

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 109 three months ago

Press Release: ID:nGNX6Zfsz5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)